إعلان
إعلان
IBRX
ImmunityBio, Inc. Common Stock
2.33
USDبرعاية
+0.09
+4.24%
٠٩ يناير, ١٥:٥٧ UTC -5
مغلق
بعد الإغلاق
2.35
+0.01
+0.43%
تقارير أرباح IBRX
النسبة الإيجابية المفاجئة
IBRX تفوق 22 من 40 آخر التقديرات.
55%
التقرير التالي
بيانات التقرير القادم
٠٢ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$36.70M
/-$0.11
التغير الضمني من Q3 25 (Revenue/ EPS)
+14.47%
/+57.14%
التغير الضمني من Q4 24 (Revenue/ EPS)
+385.96%
/+22.22%
ImmunityBio, Inc. Common Stock earnings per share and revenue
On ٠٤ نوفمبر ٢٠٢٥, IBRX reported earnings of -0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.11 USD, resulting in a 36.48% surprise. Revenue reached 32.06 مليون, compared to an expected 32.52 مليون, with a -1.40% difference. The market reacted with a +3.37% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 المحللين forecast an EPS of -0.11 USD, with revenue projected to reach 36.70 مليون USD, implying an زيادة of 57.14% EPS, and زيادة of 14.47% in Revenue from the last quarter.
الأسئلة الشائعة
What were ImmunityBio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ImmunityBio, Inc. Common Stock reported EPS of -$0.07, beating estimates by 36.48%, and revenue of $32.06M, -1.4% below expectations.
How did the market react to ImmunityBio, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.37%, changed from $2.08 before the earnings release to $2.15 the day after.
When is ImmunityBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٠٢ مارس ٢٠٢٦.
What are the forecasts for ImmunityBio, Inc. Common Stock's next earnings report?
Based on 7
المحللين, ImmunityBio, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $36.70M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان